Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEsure Group Regulatory News (ESUR)

  • There is currently no data for ESUR

Director/PDMR Shareholding

22 Mar 2017 13:53

RNS Number : 2259A
esure Group plc
22 March 2017
Β 

esure Group plc

Β 

Notification of Transactions of Directors, Person Discharging Managerial Responsibilities ("PDMRs")

Β 

The information contained in this notification is disclosed in accordance with the requirements of the EU Market Abuse Regulation.

Β 

Strategic Leadership Plan

Β 

esure Group plc (the "Company") announces that on 20 March 2017 Stuart Vann and Darren Ogden, Directors of the Company, and persons' discharging managerial responsibilities were each granted an option over ordinary shares of 1/12p each in the Company under the esure Group plc 2016 Strategic Leadership Plan.

Β 

The vesting of the Awards is subject to the satisfaction of performance conditions set by the Remuneration Committee of the Company. The awards will normally vest on the third anniversary of grant and the determination of the performance conditions. No consideration was paid for the grant of the awards. The Awards will become exercisable on 20 March 2020. Details are provided below.

Β 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

1. Stuart Vann

2. Darren Ogden

2.

Reason for the notification

a)

Position / status

1. Chief Executive Officer

2. Chief Finance Officer

b)

Initial notification / amendment

Initial notification

3.

Details of the Issuer

a)

Name

esure Group plc

b)

LEI

213800KOI3F5LM54PT80

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

esure Group plc ordinary shares of 1/12 pence

ISIN: GB00B8KJH563

b)

Nature of the transaction

Grant of options under the esure Group plc 2016 Strategic Leadership Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Β£2.414 (exercise price per share)

543,185

Β£2.414 (exercise price per share)

309,258

d)

Aggregated information

- Aggregated volume

- Price

N/A

Β 

e)

Date of the transaction

20 March 2017

f)

Place of the transaction

Grant of the options occurred outside a trading venue

Β 

Enquiries:

Alice Rivers, Company Secretary

Tel: 01737 235504

Β 

22 March 2017

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHUUVORBUAOUAR
Date   Source Headline
7th Aug 20137:00 amRNSFurther re Interim Results
6th Aug 20134:35 pmRNSPrice Monitoring Extension
6th Aug 20137:00 amRNSHalf Yearly Report
23rd Jul 20132:00 pmRNSDirectorate Change
18th Jul 20137:00 amRNSNotice of Results
26th Jun 201311:37 amRNSHolding(s) in Company
10th Jun 20134:02 pmRNSDirectorate Change
6th Jun 20137:00 amRNSNotice of Results
15th May 20132:25 pmRNSHolding(s) in Company
8th May 20137:00 amRNSInterim Management Statement
22nd Apr 201310:04 amRNSNotice of Results
12th Apr 20134:15 pmRNSHolding(s) in Company
12th Apr 201312:02 pmRNSHolding(s) in Company
12th Apr 201312:01 pmRNSDirector/PDMR Shareholding
12th Apr 201312:00 pmRNSHolding(s) in Company
11th Apr 20139:07 amRNSHolding(s) in Company
8th Apr 20136:01 pmRNSPost Stabilisation Notice
8th Apr 20136:00 pmRNSExercise of Over-allotment Option
4th Apr 20136:38 pmRNSHolding(s) in Company
4th Apr 20136:37 pmRNSHolding(s) in Company
2nd Apr 201312:21 pmRNSHolding(s) in Company
28th Mar 20134:00 pmRNSHolding(s) in Company
27th Mar 20134:10 pmRNSHolding(s) in Company
27th Mar 20134:10 pmRNSDirector/PDMR Shareholding
27th Mar 20134:10 pmRNSHolding(s) in Company
27th Mar 20138:19 amRNSTotal Voting Rights
27th Mar 20138:17 amRNSAdmission to trading on the London Stock Exchange
22nd Mar 20137:00 amRNSStabilisation Notice
22nd Mar 20137:00 amRNSOffer price

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.